WebApr 6, 2024 · FDA-approved last year, the targeted therapy delivers radiation directly to the cancer cells of patients with metastatic prostate cancer. Though advanced-stage prostate … WebJan 3, 2024 · In December 2024, Gallium 68 PSMA-11 (68Ga-PSMA-11) was approved by the FDA as the first-ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer. 1 Prior to its approval, a New Drug Application (NDA) for TLX591-CDx (illumet), a companion diagnostic kit for the preparation of 68Ga-PSMA-11, was accepted for review …
New therapy for patients with advanced prostate cancer prolongs ...
WebTelix's lead product, gallium-68 (68 Ga) gozetotide (also known as 68 Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), [3] and by the … WebAug 20, 2024 · In the Era of Radiopharmaceutical Therapy Acquiring FDA or EMA Approval. Therapy using radioisotopes is often referred to by different names, such as radioisotope therapy and radioligand therapy (RLT). ... 68 Ga-PSMA-11 is the first PSMA PET agent that received FDA approval for the visualization of PSMA-positive lesions in patients with PCa … martina peschta
FDA Approves Promising Therapy for Advanced Prostate …
WebApr 11, 2024 · The FDA recently approved the targeted radioligand therapy 177Lu-PSMA-617 (Lu 177 vipivotide tetraxetan; Pluvicto) for the treatment of patients with for the treatment … WebPluvicto is the first FDA-approved targeted radioligand therapy (RLT) in the US for mCRPC patients along the Theranostics approach that combines a targeting compound (ligand; PSMA in this case ... WebOct 20, 2024 · In March 2024, [177 Lu]Lu-PSMA-617 (Pluvicto TM) was approved by the FDA for the treatment of prostate cancer patients.Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor … martina pierrou